Previous 10 | Next 10 |
BioLineRx Announces Formation of Immuno-Oncology Scientific Advisory Board (SAB) SAB will provide insight and guidance on the Company's immuno-oncology activities and is comprised of recognized leaders in the fields of cancer immunology, intra-tumoral injections and clinical dev...
SigmaTron International SGMA +57%. American Virtual Cloud Technologies AVCT +32%. BioLineRx (NASDAQ:BLRX) +22%. Vasta Platform Limited (NASDAQ:VSTA) +20%. Arhaus ARHS +19%. Everbridge EVBG -46%. AGM Group Holdings AGMH -38%. Angion Biomedica ANGN ...
Gainers: American Virtual Cloud Technologies (NASDAQ:AVCT) +50%. Petros Pharmaceuticals (NASDAQ:PTPI) +28%. BioLineRx (NASDAQ:BLRX) +24%. SigmaTron (NASDAQ:SGMA) +20%. Oracle (NYSE:ORCL) +15%. Sprinklr (NYSE:CXM) +15%. Nam Tai Property (NYSE:NTP) +14%. Vasta (NASDAQ:VSTA) +15%. Bottomline Tec...
BioLineRx Ltd. (BLRX) Q3 2021 Earnings Conference Call November 18, 2021, 10:00 AM ET Company Participants Tim McCarthy - LifeSci Advisors, IR Philip Serlin - Chief Executive Officer Mali Zeevi - Chief Financial Officer Ella Sorani - Chief Development Officer Abi Vainstein-Haras - Chief Medic...
biolinerx (NASDAQ:BLRX): Q3 GAAP EPS of -$0.02 beats by $0.11. Cash and cash equivalents at September 30, 2021 of $62.2M Press Release Research and development expenses for the three months ended September 30, 2021 were $4.9M, an increase of $1.4M, or 41.3%, compared to $3.5M for the three mo...
BioLineRx Reports Third Quarter 2021 Financial Results and Provides Corporate Update PR Newswire - Positive results from pharmacoeconomic cost effectiveness study of Motixafortide in stem cell mobilization support its use as standard of care in combin...
biolinerx (NASDAQ:BLRX) is scheduled to announce Q3 earnings results on Wednesday, November 17th, after market close. The consensus EPS Estimate is -$0.13. Over the last 3 months, EPS estimates have seen 0 upward revisions and 1 downward. For further details see: biolinerx Q3 2021 Earni...
ATHM, ATKR, AZEK, BABA, BERY, BJ, BLRX, OTCPK:CNPOF, CSIQ, FINV, HMLP, HP, JD, KNOP, KSS, M, NGG, NJR, PLCE, OTCPK:PSHZF, VIPS, WOOF For Seeking Alpha's full earnings season calendar, click here. For further details see: Notable earnings before Thursday's open
BioLineRx to Report Third Quarter 2021 Results on November 18, 2021 Management to hold a conference call at 10:00 a.m. EST PR Newswire TEL AVIV, Israel , Nov. 12, 2021 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a late clinic...
BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annual Meeting & Exposition BioLineRx Announces an Oral Presentation and Three Poster Presentations at the 63rd American Society of Hematology (ASH) Annua...
News, Short Squeeze, Breakout and More Instantly...
BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) PR Newswire - Investigator-initiated study in...
Orkla ASA ADR (ORKLY) is expected to report for Q1 2024 Cosmos Health Inc. (COSM) is expected to report $-0.14 for Q1 2024 Basilea Pharmaceutica AG Registered Shares (BPMUF) is expected to report for Q1 2024 DCC Plc (DCCPF) is expected to report for Q4 2024 Datatec Ltd ADR (DTTLY)...
BioLineRx Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting PR Newswire New analysis of biopsy samples demonstrate...